Takeda Pharmaceutical said on April 16 that it will initiate discussions with Nihon Pharmaceutical, which became its wholly owned subsidiary on April 1, with a view to integrating their businesses in the field of plasma fraction products. Plasma-derived products are…
To read the full story
Related Article
- Takeda to Take Full Control of Nihon Pharm as Plasma Biz Grows
November 25, 2020
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





